PLUS THERAPEUTICS Files 8-K: Material Agreement, Financial Obligations
Ticker: PSTV · Form: 8-K · Filed: Feb 18, 2025 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Feb 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
PLUS THERAPEUTICS inked a deal, took on debt, and sold stock on Feb 13th. Big moves!
AI Summary
On February 13, 2025, PLUS THERAPEUTICS, INC. entered into a material definitive agreement. The company also incurred a direct financial obligation and engaged in unregistered sales of equity securities. This filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions by PLUS THERAPEUTICS, INC., including a new material agreement and financial obligations, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, suggesting potentially significant financial and operational changes for the company.
Key Numbers
- 001-34375 — SEC File Number (Identifies the company's filing history with the SEC.)
- 33-0827593 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- February 13, 2025 (date) — Date of earliest event reported
- February 18, 2025 (date) — Filing Date
- CYTORI THERAPEUTICS, INC. (company) — Former Company Name
- MACROPORE INC (company) — Former Company Name
FAQ
What was the nature of the material definitive agreement entered into by PLUS THERAPEUTICS, INC. on February 13, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this summary.
What type of direct financial obligation did PLUS THERAPEUTICS, INC. incur?
The filing states the creation of a direct financial obligation, but the specific terms and amount are not detailed in this summary.
What were the circumstances of the unregistered sales of equity securities?
The filing reports unregistered sales of equity securities, but the details regarding the number of shares, price, and purchasers are not included in this summary.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
Regulation FD Disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure.
What are the former names of PLUS THERAPEUTICS, INC. mentioned in the filing?
The filing lists CYTORI THERAPEUTICS, INC. (name change effective July 12, 2005) and MACROPORE INC (name change effective March 20, 2001) as former names.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding PLUS THERAPEUTICS, INC. (PSTV).